Company profile for Ethypharm

PharmaCompass

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Related CompaniesRelated Companies

About

Ethypharm is a European pharmaceutical company focused on CNS and Hospital injectables either through direct sales or through D&L.
Ethypharm is also offering contract development and manufacturing (CDMO) services from formulation, clinical to scale up and commercial phases.
Ethypharm is your CDMO partner for sterile forms (Ampoule, PFS, Vials, Lyo) and conventional (complex solid dosage forms and orals), using conventional API and High potent, Narcotics, Controlled drugs.
Our expertise in Flashtab, Tmask, Nanosizing, Multicaps, Transmucosal, and Orodispersible technologies enables us to develop innovative formulations.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
194 Bureaux de la Colline, Batiment D – 12eme etage, 92213 Saint-Cloud Cedex
Telephone
Telephone
+33 0141121720
Contact Info
Others

Events

Webinars & Exhibitions

A PHP Error was encountered

Severity: Warning

Message: Undefined variable $tile1

Filename: tabs/exhibitions.php

Line Number: 43

Backtrace:

File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
Line: 43
Function: _error_handler

File: /var/www/html/application/models/CmnPec.php
Line: 1625
Function: view

File: /var/www/html/application/views/include/party/query.php
Line: 575
Function: create

File: /var/www/html/application/views/include/party/indexNew.php
Line: 70
Function: include

File: /var/www/html/application/views/commonNew.php
Line: 445
Function: include

File: /var/www/html/application/controllers/PharmaServices.php
Line: 4643
Function: view

File: /var/www/html/index.php
Line: 224
Function: require_once

CPhI India 2024

CPhI India 2024

Not Confirmed

envelop Contact Supplier

CPhI India 2024

Post an Enquiry

Meeting

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-97467.pdf

    https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-79941.pdf

    https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-79362.pdf

    https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-84782.pdf

NEWS #PharmaBuzz

read-more
read-more

https://www.ethypharm.com/blog/newsroom/ethypharm-announces-the-appointment-of-eric-chevalier-as-group-human-resources-director/

PRESS RELEASE
04 Oct 2024

https://www.ethypharm.com/wp-content/uploads/2024/06/18-06-24-Press-Release-Argatroban-Ethypharm-Final.pdf

PRESS RELEASE
17 Jun 2024

https://www.ethypharm.com/wp-content/uploads/2024/06/13062024_Group-PR_-Ethypharm-Expands-its-Mesalazine-Portfolio-in-China_FINAL-PR-NEWSWIRE.pdf

PRESS RELEASE
13 Jun 2024

https://www.ethypharm.com/wp-content/uploads/2022/10/Agreement-Gaia-AG-EN.pdf

PRESS RELEASE
06 Apr 2024

https://www.ethypharm.com/wp-content/uploads/2023/06/PR-Xavier-LASSERRE-appointed_CCO_Ethypharm-final.pdf

PRESS RELEASE
13 Jun 2023

https://www.ethypharm.com/wp-content/uploads/2023/05/Aurora_Ethypharm_Extension-Pilot-Program_FINAL-1.pdf

PRESS RELEASE
01 May 2023

Drugs in Development

read-more
read-more

Details:

Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.


Lead Product(s): Argatroban Monohydrate

Therapeutic Area: Hematology Brand Name: Arganova

Study Phase: ApprovedProduct Type: Small molecule

Recipient: Mitsubishi Tanabe Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 17, 2024

Ethypharm

01

Ethypharm

France
arrow

Lead Product(s) : Argatroban Monohydrate

Therapeutic Area : Hematology

Highest Development Status : Approved

Recipient : Mitsubishi Tanabe Pharma

Deal Size : Undisclosed

Deal Type : Acquisition

Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.

Brand Name : Arganova

Molecule Type : Small molecule

Upfront Cash : Undisclosed

June 17, 2024

Ethypharm

Details:

The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.


Lead Product(s): Mesalazine

Therapeutic Area: Gastroenterology Brand Name: Etiasa

Study Phase: ApprovedProduct Type: Small molecule

Recipient: Anbison

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 13, 2024

Ethypharm

02

Ethypharm

France
arrow

Lead Product(s) : Mesalazine

Therapeutic Area : Gastroenterology

Highest Development Status : Approved

Recipient : Anbison

Deal Size : Undisclosed

Deal Type : Acquisition

Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.

Brand Name : Etiasa

Molecule Type : Small molecule

Upfront Cash : Undisclosed

June 13, 2024

Ethypharm

Details:

Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.


Lead Product(s): Morphine Sulfate

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 02, 2021

Ethypharm

03

Ethypharm

France
arrow

Lead Product(s) : Morphine Sulfate

Therapeutic Area : Neurology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 02, 2021

Ethypharm

Details:

Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by Dr Reddy's.


Lead Product(s): Celecoxib

Therapeutic Area: Neurology Brand Name: Elyxyb

Study Phase: ApprovedProduct Type: Small molecule

Recipient: Dr. Reddy\'s Laboratories

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 19, 2021

Ethypharm

04

Ethypharm

France
arrow

Lead Product(s) : Celecoxib

Therapeutic Area : Neurology

Highest Development Status : Approved

Recipient : Dr. Reddy\'s Laboratories

Deal Size : Undisclosed

Deal Type : Acquisition

Details : Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by D...

Brand Name : Elyxyb

Molecule Type : Small molecule

Upfront Cash : Undisclosed

May 19, 2021

Ethypharm

Details:

Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.


Lead Product(s): Vigabatrin

Therapeutic Area: Neurology Brand Name: Kigabeq

Study Phase: ApprovedProduct Type: Small molecule

Recipient: Orphelia Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 19, 2021

Ethypharm

05

Ethypharm

France
arrow

Lead Product(s) : Vigabatrin

Therapeutic Area : Neurology

Highest Development Status : Approved

Recipient : Orphelia Pharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.

Brand Name : Kigabeq

Molecule Type : Small molecule

Upfront Cash : Undisclosed

January 19, 2021

Ethypharm

Details:

Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.


Lead Product(s): Triamcinolone Acetonide

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Medexus Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 18, 2020

Ethypharm

06

Ethypharm

France
arrow

Lead Product(s) : Triamcinolone Acetonide

Therapeutic Area : Immunology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Medexus Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales ...

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Undisclosed

December 18, 2020

Ethypharm

Details:

Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.


Lead Product(s): Cholic Acid

Therapeutic Area: Genetic Disease Brand Name: Orphacol

Study Phase: ApprovedProduct Type: Small molecule

Recipient: Laboratoires CTRS

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 10, 2020

Ethypharm

07

Ethypharm

France
arrow

Lead Product(s) : Cholic Acid

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Recipient : Laboratoires CTRS

Deal Size : Undisclosed

Deal Type : Agreement

Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.

Brand Name : Orphacol

Molecule Type : Small molecule

Upfront Cash : Undisclosed

November 10, 2020

Ethypharm

Details:

The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.


Lead Product(s): Fentanyl

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Small molecule

Recipient: Reading Scientific Services

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 04, 2020

Ethypharm

08

Ethypharm

France
arrow

Details : The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Undisclosed

June 04, 2020

Ethypharm
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Services

Discover the service capabilities from this company

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty